# MEDALIST (NCT02631070)

> A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

No report yet. It can be ordered.

- Drugs tested: luspatercept
- Indication: transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02631070
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Myelodysplastic Syndromes
- Interventions: Luspatercept; Placebo
- Enrollment: 229
- Primary outcome: Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24

## Indexed commentary on MEDALIST so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=medalist-nct02631070